Key result
NSAIDs yield clinical response but only 1 remission in children with Down's syndrome arthritis.
Case Report (n=7)
Arthropathy associated with Down's syndrome should be considered a distinct entity and an exclusion for the diagnosis of juvenile rheumatoid arthritis.
Arthritis in Down syndrome may show limited NSAID remission; leaves open whether it represents a distinct entity from juvenile rheumatoid arthritis.
Down's syndrome (trisomy 21) is associated with a variety of skeletal abnormalities and an increased incidence of joint hypermobility. Children with Down's syndrome are known to have a number of immunologic abnormalities and an increased incidence of autoimmune phenomena. We report 7 patients with Down's syndrome and arthritis. Four children had polyarticular disease and 3 had pauciarticular disease at onset. Only 1 child had significant cardiac disease. HLA typing in 5 children did not show specific correlations. Mean duration of followup was 3 years and 7 months. All children responded to nonsteroidal antiinflammatory drugs, but only 1 child is in clinical remission. Two children have died: 1 secondary to cervical spine instability and the other secondary to cardiac compromise. Arthropathy associated with Down's syndrome should be an additional exclusion for the diagnosis of juvenile rheumatoid arthritis. Further investigation of this association may give clues to the relationship between genetic and immunologic factors in the pathogenesis of joint inflammation.
No takes yet. Share an insight, caveat, or question.
Yancey et al. (1984) conducted a case report in Down's syndrome and arthritis (n=7). Nonsteroidal antiinflammatory drugs was evaluated on Clinical response and remission. Among 7 children with Down's syndrome and arthritis, all responded to nonsteroidal antiinflammatory drugs, but only 1 achieved clinical remission over a mean follow-up of 3 years and 7 months.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: